ON-DEMAND Webinar

Large Molecule Pharmacokinetic Assays for New Modalities

Novel Approach to ADA Assay Development to Overcome Target Interference Issues from Dimerization
Massbio-logo

Now Streaming On-Demand

PK assays are a vital component of the drug development process and the data derived is utilized to help select the dosage for preclinical and clinical studies. Large molecule PK bioanalytical assays are generally analyzed using LBAs.

Therapeutic monoclonal antibodies and proteins are well-known drug modalities but recently, new modalities have entered the drug development scene. In this webinar, case studies from different drug modalities will be presented with a focus on assay setup and the challenges and solutions for validating the assay.

About the Speakers

Our experts will discuss lessons learned from their experiences and offer insight into the multiple stages of specific assays including critical reagents, regulatory standards, assay formats and timelines.

About the Presenter:

Marianne Scheel Fjording is a Scientific Officer at BioAgilytix. Marianne has an extensive background in large molecule bioanalytical assay set-up and assay validation. She has 20+ years of experience working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, she was Scientific Director at Novo Nordisk (Copenhagen, Denmark) where she delivered bioanalytical strategies for PK and biomarker assays.

Bioanalytical-Strategies-for-Biomarker

Share this Resource

icon-twitter icon-linkedin link 1

Watch Now!

Complete the form to view the recording.